[{"address1": "12730 High Bluff Drive", "address2": "Suite 400", "city": "San Diego", "state": "CA", "zip": "92130", "country": "United States", "phone": "858 500 8800", "website": "https://kuraoncology.com", "industry": "Biotechnology", "industryKey": "biotechnology", "industryDisp": "Biotechnology", "sector": "Healthcare", "sectorKey": "healthcare", "sectorDisp": "Healthcare", "longBusinessSummary": "Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. Its lead product candidate includes ziftomenib, a selective investigational inhibitor of the menin-KMT2A interaction for the treatment of genetically defined subsets of acute leukemias, including acute myeloid leukemia and acute lymphoblastic leukemia; tipifarnib, an orally bioavailable farnesyl transferase inhibitor combination with alpelisib for patients with PIK3CA-dependent HNSCC; and KO-2806, a selective investigational FTI for the treatment of solid tumors. It has a clinical collaboration with Novartis Pharma AG to evaluate the combination of tipifarnib and alpelisib in patients with head and neck squamous cell carcinoma whose tumors have HRAS overexpression and/or PIK3CA mutation and/or amplification; strategic collaboration agreement with Kyowa Kirin Co., Ltd. to develop and commercialize its oral menin inhibitor for the treatment of patients with acute myeloid leukemia (AML) and other hematologic malignancies; and a clinical collaboration with Mirati Therapeutics, Inc. to evaluate the combination of KO-2806 and adagrasib, a KRASG12C inhibitor in patients with NSCLC. The company is headquartered in San Diego, California.", "fullTimeEmployees": 192, "companyOfficers": [{"maxAge": 1, "name": "Dr. Troy Edward Wilson J.D., Ph.D.", "age": 55, "title": "Chairman, CEO & President", "yearBorn": 1969, "fiscalYear": 2024, "totalPay": 1296258, "exercisedValue": 1234936, "unexercisedValue": 15624}, {"maxAge": 1, "name": "Ms. Kathleen  Ford", "age": 77, "title": "Chief Operating Officer", "yearBorn": 1947, "fiscalYear": 2024, "totalPay": 868935, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Thomas  Doyle", "age": 53, "title": "Senior Vice President of Finance & Accounting", "yearBorn": 1971, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Dr. Roger  Bakale Ph.D.", "title": "Senior Vice President of Manufacturing & Supply Chain", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Ms. Maureen  Clancy M.B.A.", "title": "VP and Global Head of Program Leadership & Project Management", "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}, {"maxAge": 1, "name": "Mr. Brian T. Powl M.B.A., M.S.", "age": 50, "title": "Chief Commercial Officer", "yearBorn": 1974, "fiscalYear": 2024, "exercisedValue": 0, "unexercisedValue": 0}], "auditRisk": 5, "boardRisk": 7, "compensationRisk": 6, "shareHolderRightsRisk": 8, "overallRisk": 7, "governanceEpochDate": 1743465600, "compensationAsOfEpochDate": 1735603200, "executiveTeam": [], "maxAge": 86400, "priceHint": 2, "previousClose": 5.75, "open": 5.7, "dayLow": 5.64, "dayHigh": 5.91, "regularMarketPreviousClose": 5.75, "regularMarketOpen": 5.7, "regularMarketDayLow": 5.64, "regularMarketDayHigh": 5.91, "payoutRatio": 0.0, "beta": 0.824, "forwardPE": -2.2097378, "volume": 937610, "regularMarketVolume": 937610, "averageVolume": 1560035, "averageVolume10days": 2063420, "averageDailyVolume10Day": 2063420, "bid": 0.0, "ask": 0.0, "bidSize": 0, "askSize": 0, "marketCap": 476587840, "fiftyTwoWeekLow": 5.41, "fiftyTwoWeekHigh": 23.48, "priceToSalesTrailing12Months": 8.844865, "fiftyDayAverage": 7.2497, "twoHundredDayAverage": 13.70675, "trailingAnnualDividendRate": 0.0, "trailingAnnualDividendYield": 0.0, "currency": "USD", "tradeable": false, "enterpriseValue": -234346736, "profitMargins": 0.0, "floatShares": 59769977, "sharesOutstanding": 80777600, "sharesShort": 8802791, "sharesShortPriorMonth": 9211838, "sharesShortPreviousMonthDate": 1740700800, "dateShortInterest": 1743379200, "sharesPercentSharesOut": 0.109, "heldPercentInsiders": 0.011469999, "heldPercentInstitutions": 1.02283, "shortRatio": 7.25, "shortPercentOfFloat": 0.11, "impliedSharesOutstanding": 80777600, "bookValue": 5.288, "priceToBook": 1.1157337, "lastFiscalYearEnd": 1735603200, "nextFiscalYearEnd": 1767139200, "mostRecentQuarter": 1735603200, "netIncomeToCommon": -173983008, "trailingEps": -2.02, "forwardEps": -2.67, "enterpriseToRevenue": -4.349, "enterpriseToEbitda": 1.218, "52WeekChange": -0.67564595, "SandP52WeekChange": 0.05430484, "quoteType": "EQUITY", "currentPrice": 5.9, "targetHighPrice": 40.0, "targetLowPrice": 10.0, "targetMeanPrice": 28.0, "targetMedianPrice": 28.5, "recommendationMean": 1.46667, "recommendationKey": "strong_buy", "numberOfAnalystOpinions": 12, "totalCash": 727395008, "totalCashPerShare": 9.007, "ebitda": -192347008, "totalDebt": 16594000, "quickRatio": 9.319, "currentRatio": 9.463, "totalRevenue": 53883000, "debtToEquity": 4.012, "revenuePerShare": 0.625, "returnOnAssets": -0.19973, "returnOnEquity": -0.4291, "grossProfits": -101464000, "freeCashflow": -55928752, "operatingCashflow": 134316992, "grossMargins": -1.88304, "ebitdaMargins": 0.0, "operatingMargins": -0.41674, "financialCurrency": "USD", "symbol": "KURA", "language": "en-US", "region": "US", "typeDisp": "Equity", "quoteSourceName": "Nasdaq Real Time Price", "triggerable": true, "customPriceAlertConfidence": "HIGH", "corporateActions": [], "postMarketTime": 1744921546, "regularMarketTime": 1744920001, "exchange": "NMS", "messageBoardId": "finmb_282774456", "exchangeTimezoneName": "America/New_York", "exchangeTimezoneShortName": "EDT", "gmtOffSetMilliseconds": -14400000, "market": "us_market", "esgPopulated": false, "regularMarketChangePercent": 2.6086974, "regularMarketPrice": 5.9, "shortName": "Kura Oncology, Inc.", "marketState": "CLOSED", "postMarketChangePercent": 0.0, "postMarketPrice": 5.9, "postMarketChange": 0.0, "regularMarketChange": 0.1500001, "regularMarketDayRange": "5.64 - 5.91", "fullExchangeName": "NasdaqGS", "averageDailyVolume3Month": 1560035, "fiftyTwoWeekLowChange": 0.49000025, "fiftyTwoWeekLowChangePercent": 0.090573065, "fiftyTwoWeekRange": "5.41 - 23.48", "fiftyTwoWeekHighChange": -17.58, "fiftyTwoWeekHighChangePercent": -0.7487223, "fiftyTwoWeekChangePercent": -67.5646, "earningsTimestamp": 1740603780, "earningsTimestampStart": 1746010740, "earningsTimestampEnd": 1746446400, "earningsCallTimestampStart": 1740605400, "earningsCallTimestampEnd": 1740605400, "isEarningsDateEstimate": true, "epsTrailingTwelveMonths": -2.02, "epsForward": -2.67, "epsCurrentYear": -2.19451, "priceEpsCurrentYear": -2.6885273, "fiftyDayAverageChange": -1.3497, "fiftyDayAverageChangePercent": -0.18617322, "twoHundredDayAverageChange": -7.80675, "twoHundredDayAverageChangePercent": -0.56955516, "sourceInterval": 15, "exchangeDataDelayedBy": 0, "averageAnalystRating": "1.5 - Strong Buy", "cryptoTradeable": false, "longName": "Kura Oncology, Inc.", "hasPrePostMarketData": true, "firstTradeDateMilliseconds": 1442410200000, "displayName": "Kura Oncology", "trailingPegRatio": null, "__fetch_time": "2025-04-19"}]